Literature DB >> 21174549

Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm?

Pierpaolo Correale, Maria Grazia Cusi, Pierosandro Tagliaferri.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21174549     DOI： 10.2217/imt.10.92

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  8 in total

Review 1.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

Review 2.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

3.  A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Authors:  Domenico Ciliberto; Nicoletta Staropoli; Francesca Caglioti; Simona Gualtieri; Lucia Fiorillo; Silvia Chiellino; Antonina Maria De Angelis; Francesco Mendicino; Cirino Botta; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2015-06-10       Impact factor: 4.742

Review 4.  OX40 as a novel target for the reversal of immune escape in colorectal cancer.

Authors:  Lin-Hai Yan; Xiao-Liang Liu; Si-Si Mo; Di Zhang; Xian-Wei Mo; Wei-Zhong Tang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

5.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

Authors:  Cirino Botta; Vito Barbieri; Domenico Ciliberto; Antonio Rossi; Danilo Rocco; Raffaele Addeo; Nicoletta Staropoli; Pierpaolo Pastina; Giulia Marvaso; Ignazio Martellucci; Annamaria Guglielmo; Luigi Pirtoli; Pasquale Sperlongano; Cesare Gridelli; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri; Pierpaolo Correale
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

6.  Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Authors:  Pierpaolo Pastina; Valerio Nardone; Stefania Croci; Giuseppe Battaglia; Francesca Vanni; Cristiana Bellan; Marcella Barbarino; Veronica Ricci; Susan Costantini; Francesca Capone; Cirino Botta; Mayra Rachele Zarone; Gabriella Misso; Mariarosaria Boccellino; Michele Caraglia; Antonio Giordano; Piero Paladini; Pierfrancesco Tassone; Pierosandro Tagliaferri; Maria Grazia Cusi; Luigi Pirtoli; Pierpaolo Correale
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  M A Siciliano; G Caridà; D Ciliberto; M d'Apolito; C Pelaia; D Caracciolo; C Riillo; P Correale; A Galvano; A Russo; V Barbieri; P Tassone; P Tagliaferri
Journal:  ESMO Open       Date:  2022-04-12

8.  Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Authors:  E C Martino; G Misso; P Pastina; S Costantini; F Vanni; C Gandolfo; C Botta; F Capone; A Lombardi; L Pirtoli; P Tassone; C Ulivieri; P Tagliaferri; M G Cusi; M Caraglia; P Correale
Journal:  Cell Death Discov       Date:  2016-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.